A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)

NCT06615050 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

572

Enrollment

INDUSTRY

Sponsor class

Conditions

Graft-versus-host Disease (GVHD)

Interventions

DRUG: Tacrolimus (Tac)
DRUG: Methotrexate (MTX)
DRUG: Ruxolitinib (Rux)
DRUG: Cyclophosphamide
DRUG: Mycophenolate mofetil (MMF)

Sponsor

Incyte Corporation

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]